Wednesday, Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE:NVO) to advance the development of novel genetic medicines targeting cardiometabolic ...
Sources say the move provides yet more evidence that the firm's U.S. ambition is coming at the expense of the firm's historic strongholds, particularly Germany which is resident to around 645 of ...
Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases. NanoVation’s lcLNP technology has demonstrated the ability ...